This article is more than 5 years old. Information may no longer be current.

Eyetech sets Macugen price

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW YORK — Eyetech Pharmaceuticals has set the list price for its age-related macular degeneration drug at $995 per injection, the company announced in a press release.

Macugen (pegaptanib sodium, Eyetech-Pfizer) was approved earlier this month by the Food and Drug Administration for use in the treatment of neovascular AMD.

In other business news regarding Macugen, Isis Pharmaceuticals sold a portion of its rights to the drug to Drug Royalty USA for $24 million. Under terms of the agreement, Isis and Drug Royalty will share the royalty rights to Macugen through 2009, at which time all rights revert back to Isis. Isis licensed to Eyetech patents integral to the development, manufacture and commercialization of Macugen, the companies stated in a joint press release.

Additionally, Nektar Therapeutics, which sublicensed the PEGylation technology used in Macugen from Enzon to Eyetech in 2002, is entitled to royalty fees as well. Enzon will receive a portion of those royalties, the company announced in a press release.

Macugen is the first therapy indicated for the treatment of all types of neovascular AMD, regardless of lesion subtype or size, according to Eyetech.